We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EU Approves Novartis’ Jakavi for Rare Blood Cancer
EU Approves Novartis’ Jakavi for Rare Blood Cancer
The European Medicines Agency Tuesday approved Novartis’ Jakavi for patients with polycythemia vera — a rare blood cancer — who cannot take hydroxyurea.